We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add Penumbra Stock to Your Portfolio Now
Read MoreHide Full Article
Robust improvement of Penumbra, Inc.’s (PEN - Free Report) Thrombectomy business is poised to help the company grow in the upcoming quarters. PEN expects impressive growth as it plans to expand globally in the coming years. A robust solvency position also bodes well for the stock. Meanwhile, unfavorable foreign exchange remains a concern for Penumbra.
In the past six months, shares of this Zacks Rank #2 (Buy) company have rallied 32.4% compared with the industry’s 0.3% growth and the S&P 500 composite’s 6.8% gain.
The global healthcare provider has a market capitalization of $9.29 billion. PEN beat on earnings in three of the trailing four quarters and missed in one, the average surprise being 10.54%.
Tailwinds for Penumbra
Robust Thrombectomy Business Growth: Penumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States as well as its CAVT line of products. In the third quarter of 2024, the company delivered 21.2% year-over-year growth in thrombectomy in the United States, driven by continued adoption and further market penetration of the current CAVT Portfolio, Lightning Flash 2.0 and Lightning Bolt 7. The U.S. VTE franchise delivered revenue growth of 32% year over year.
Global Expansion Continues: Penumbra derives a significant portion of its revenues internationally. The company expects to materially increase revenues and profitability in its international business in the next three years and beyond.
Internationally, the company projects early success with the launch of its first-generation computer-aided products in Europe. In addition, PEN’s international teams and partners envision enormous potential to further expand its leadership in stroke intervention outside the United States with SENDit and Thunderbolt over the coming years. Per the latest update, the company received the CE Mark for Lightning Flash 2.0 and Lightning Bolt 7 in mid-September 2024 and is in the early phases of introducing its transformative technology to European markets.
Stable Solvency Structure: Penumbra exited the third quarter of 2024 with cash and cash equivalents of $291 million. Meanwhile, total debt was $22 million, much lower than the corresponding cash and cash equivalent level. Also, it has no short-term-payable debt on its balance sheet. This is good news in terms of the company’s solvency position, particularly during global inflation and supply delays.
Image Source: Zacks Investment Research
Headwinds for Penumbra
Foreign Exchange Impacts Sales: A significant portion of Penumbra’s sales and costs is exposed to changes in foreign exchange rates. The company’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income.
PEN Stock Estimate Trends
In the past 30 days, the Zacks Consensus Estimate for Penumbra’s 2025 earnings has remained unchanged at $3.86.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $1.37 billion, indicating a 14.9% rise from the year-ago reported number.
Veracyte's estimated 2025 earnings growth rate is 65.8%, compared with the industry’s 21.9%. Its shares have risen 49.2% in the past year, compared with the industry’s 5.5% growth. VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%.
Omnicell, carrying a Zacks Rank #2 at present, has an earnings yield of 3.7% compared with the industry’s 9.5%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 121.74%. OMCL’s shares have risen 15.2% against the industry’s 16.8% decline in the past year.
ResMed, carrying a Zacks Rank 2 at present, has an estimated earnings growth rate of 8.9% for fiscal 2025. Its shares have surged 33.4% compared with the industry’s 11.1% growth in the past year. RMD’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 6.41%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Add Penumbra Stock to Your Portfolio Now
Robust improvement of Penumbra, Inc.’s (PEN - Free Report) Thrombectomy business is poised to help the company grow in the upcoming quarters. PEN expects impressive growth as it plans to expand globally in the coming years. A robust solvency position also bodes well for the stock. Meanwhile, unfavorable foreign exchange remains a concern for Penumbra.
In the past six months, shares of this Zacks Rank #2 (Buy) company have rallied 32.4% compared with the industry’s 0.3% growth and the S&P 500 composite’s 6.8% gain.
The global healthcare provider has a market capitalization of $9.29 billion. PEN beat on earnings in three of the trailing four quarters and missed in one, the average surprise being 10.54%.
Tailwinds for Penumbra
Robust Thrombectomy Business Growth: Penumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States as well as its CAVT line of products. In the third quarter of 2024, the company delivered 21.2% year-over-year growth in thrombectomy in the United States, driven by continued adoption and further market penetration of the current CAVT Portfolio, Lightning Flash 2.0 and Lightning Bolt 7. The U.S. VTE franchise delivered revenue growth of 32% year over year.
Global Expansion Continues: Penumbra derives a significant portion of its revenues internationally. The company expects to materially increase revenues and profitability in its international business in the next three years and beyond.
Internationally, the company projects early success with the launch of its first-generation computer-aided products in Europe. In addition, PEN’s international teams and partners envision enormous potential to further expand its leadership in stroke intervention outside the United States with SENDit and Thunderbolt over the coming years. Per the latest update, the company received the CE Mark for Lightning Flash 2.0 and Lightning Bolt 7 in mid-September 2024 and is in the early phases of introducing its transformative technology to European markets.
Stable Solvency Structure: Penumbra exited the third quarter of 2024 with cash and cash equivalents of $291 million. Meanwhile, total debt was $22 million, much lower than the corresponding cash and cash equivalent level. Also, it has no short-term-payable debt on its balance sheet. This is good news in terms of the company’s solvency position, particularly during global inflation and supply delays.
Image Source: Zacks Investment Research
Headwinds for Penumbra
Foreign Exchange Impacts Sales: A significant portion of Penumbra’s sales and costs is exposed to changes in foreign exchange rates. The company’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income.
PEN Stock Estimate Trends
In the past 30 days, the Zacks Consensus Estimate for Penumbra’s 2025 earnings has remained unchanged at $3.86.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $1.37 billion, indicating a 14.9% rise from the year-ago reported number.
Other Top MedTech Stocks
Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Omnicell (OMCL - Free Report) and ResMed (RMD - Free Report) .
Veracyte's estimated 2025 earnings growth rate is 65.8%, compared with the industry’s 21.9%. Its shares have risen 49.2% in the past year, compared with the industry’s 5.5% growth. VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%.
VCYT carries a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Omnicell, carrying a Zacks Rank #2 at present, has an earnings yield of 3.7% compared with the industry’s 9.5%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 121.74%. OMCL’s shares have risen 15.2% against the industry’s 16.8% decline in the past year.
ResMed, carrying a Zacks Rank 2 at present, has an estimated earnings growth rate of 8.9% for fiscal 2025. Its shares have surged 33.4% compared with the industry’s 11.1% growth in the past year. RMD’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 6.41%.